Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course.

Wefers, Annika K; Stichel, Damian; Schrimpf, Daniel; Coras, Roland; Pages, Mélanie; Tauziède-Espariat, Arnault; Varlet, Pascale; Schwarz, Daniel; Söylemezoglu, Figen; Pohl, Ute; Pimentel, José; Meyer, Jochen; Hewer, Ekkehard; Japp, Anna; Joshi, Abhijit; Reuss, David E; Reinhardt, Annekathrin; Sievers, Philipp; Casalini, M Belén; Ebrahimi, Azadeh; ... (2020). Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course. Acta neuropathologica, 139(1), pp. 193-209. Springer-Verlag 10.1007/s00401-019-02078-w

[img] Text
Wefers2019_Article_IsomorphicDiffuseGliomaIsAMorp.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (5MB) | Request a copy

The "isomorphic subtype of diffuse astrocytoma" was identified histologically in 2004 as a supratentorial, highly differentiated glioma with low cellularity, low proliferation and focal diffuse brain infiltration. Patients typically had seizures since childhood and all were operated on as adults. To define the position of these lesions among brain tumours, we histologically, molecularly and clinically analysed 26 histologically prototypical isomorphic diffuse gliomas. Immunohistochemically, they were GFAP-positive, MAP2-, OLIG2- and CD34-negative, nuclear ATRX-expression was retained and proliferation was low. All 24 cases sequenced were IDH-wildtype. In cluster analyses of DNA methylation data, isomorphic diffuse gliomas formed a group clearly distinct from other glial/glio-neuronal brain tumours and normal hemispheric tissue, most closely related to paediatric MYB/MYBL1-altered diffuse astrocytomas and angiocentric gliomas. Half of the isomorphic diffuse gliomas had copy number alterations of MYBL1 or MYB (13/25, 52%). Gene fusions of MYBL1 or MYB with various gene partners were identified in 11/22 (50%) and were associated with an increased RNA-expression of the respective MYB-family gene. Integrating copy number alterations and available RNA sequencing data, 20/26 (77%) of isomorphic diffuse gliomas demonstrated MYBL1 (54%) or MYB (23%) alterations. Clinically, 89% of patients were seizure-free after surgery and all had a good outcome. In summary, we here define a distinct benign tumour class belonging to the family of MYB/MYBL1-altered gliomas. Isomorphic diffuse glioma occurs both in children and adults, has a concise morphology, frequent MYBL1 and MYB alterations and a specific DNA methylation profile. As an exclusively histological diagnosis may be very challenging and as paediatric MYB/MYBL1-altered diffuse astrocytomas may have the same gene fusions, we consider DNA methylation profiling very helpful for their identification.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Service Sector > Institute of Pathology

UniBE Contributor:

Hewer, Ekkehard

Subjects:

500 Science > 570 Life sciences; biology
600 Technology > 610 Medicine & health

ISSN:

0001-6322

Publisher:

Springer-Verlag

Language:

English

Submitter:

Ekkehard Hewer

Date Deposited:

17 Oct 2019 16:21

Last Modified:

06 Jan 2020 01:31

Publisher DOI:

10.1007/s00401-019-02078-w

PubMed ID:

31563982

Uncontrolled Keywords:

Epilepsy Gene fusion Glioma Isomorphic diffuse glioma MYB MYBL1

BORIS DOI:

10.7892/boris.133950

URI:

https://boris.unibe.ch/id/eprint/133950

Actions (login required)

Edit item Edit item
Provide Feedback